Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
PodcastThe Directors

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

September 25, 2026
Vol.52 No.35
By Claire Marie Porter and Paul Goldberg
NCI launches AI tool to help match patients to clinical trials
Cancer Policy

NCI launches AI tool to help match patients to clinical trials

September 25, 2026
Vol.52 No.35
By Sara Willa Ernst
Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
NCI

Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
“To my knowledge, 100% of grants that clear my desk get funded”

September 18, 2026
Vol.52 No.34
By Claire Marie Porter
Letai shares weekly musings in NCI’s new “Tuesdays with Tony” series
Cancer Policy

Letai shares weekly musings in NCI’s new “Tuesdays with Tony” series

September 18, 2026
Vol.52 No.34
Senthil K. Muthuswamy named director of NCI’s Center for Cancer Research
In Brief

Senthil K. Muthuswamy named director of NCI’s Center for Cancer Research

September 18, 2026
Vol.52 No.34
UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy
In Brief

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

August 07, 2026
Vol.52 No.31
In Brief

Dana-Farber Department of Pathology receives $2.8M grant from NCI

August 07, 2026
Vol.52 No.31
Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Cancer History ProjectFree

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

July 31, 2026
Vol.52 No.30
By Sara Willa Ernst
Ned Sharpless’s portrait unveiled at FNIH ceremony
In Brief

Ned Sharpless’s portrait unveiled at FNIH ceremony

July 10, 2026
Vol.52 No.27
The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
FreePodcastThe Directors

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions”

June 26, 2026
Vol.52 No.25
By Paul Goldberg and Claire Marie Porter

Posts navigation

12…40Next

Trending Stories

  • Is it time to re-assess the practice and practicality of screening colonoscopy?
    Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives
  • The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
    Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish
  • FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
    Clinical benefit will not be considered for approval, FDA says
  • Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
  • From “default dead” to living the future of cancer care
    As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
  • The Galleri MCD vote: What FDA asked its advisors to ignore

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account